Author

Debendranath Dey

ORCID 0000-0002-9651-2080Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 2 Biochemistry· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

Dennis Solas· 4 shared Vishwanath R. LingappaiD· 4 shared Anuradha F. LingappaiD· 3 shared Carsten KorthiD· 3 shared Maya MichoniD· 3 shared Suguna Mallesh· 3 shared Jeffrey RosenfeldiD· 2 shared Justin K. IchidaiD· 2 shared

Activity by Year

2024-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersNeuroscience

Dennis Solas

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Oxidized MIF is an Alzheimer's Disease drug target relaying external risk factors to tau pathology

Andreas Müller-Schiffmann, Felix Torres, Anatoliy Kitaygorodskyy, Anand Ramani, Argyro Alatza, Sarah K. Tschirner, Julien Orts, Arthur Haltrich, Ingrid Prikulis, Shaofeng Yu, Debendranath Dey, Suguna Mallesh, Dharma Prasad, Dennis Solas, Verian Bader, , Carsten Korth

The paper identifies oxidized MIF as a drug target that links HSV-1 infection and external stressors to tau pathology in Alzheimer's disease.

Cell Reports Medicine · Dec 19, 2025Peer-reviewedNeuroscience

An ALS Therapeutic Assembly Modulator Target in Peripheral Blood Mononuclear Cells: Implications for ALS Pathophysiology, Therapeutics, and Diagnostics

Shao Feng Yu, Maya Michon, Anuradha F. Lingappa, Kumar Paulvannan, Dennis Solas, Kim A. Staats, Justin K. Ichida, Debendranath Dey, Jeffrey Rosenfeld, Vishwanath R. Lingappa

The paper identifies a multi-protein complex in PBMCs as a target for ALS therapeutic assembly modulators, showing altered composition in ALS patients and responsiveness to treatment.

Clinical Proteomics · Apr 28, 2025Peer-reviewedPhysiology

Small Molecule Disruption of a Protein Disulfide Isomerase-Containing Multi-Protein Complex Causes Broad Cancer Selective Metabolic Collapse and Tumor Inhibition in vivo

Anuradha F. Lingappa, Suguna Mallesh, Maya Michon, D. SHIVARUDRASWAMY, Jim Jung‐Ching Lin, M. Dharma Prasad, Debendranath Dey, Dennis Solas, Vishwanath R. Lingappa, Andreas Mueller-Schiffmann, David Andrews, Carsten Korth, Stevan Pecic

PAV-620 and PAV-805 disrupt PDI-containing complexes, causing metabolic collapse and tumor inhibition in cancer models without toxicity to healthy cells.

bioRxiv · Feb 28, 2025 · PreprintBiochemistry

Protein Assembly Modulation: A New Approach to ALS Therapeutics

Shao Feng Yu, Kumar Paulvannan, Dennis Solas, Anuradha F. Lingappa, Ana Raquel Moreira, Shriya Sahu, Maya Michon, Amanda Macieik, Danielle Goldsmith, Nicholas DeYarman, Suguna Mallesh, M. Dharma Prasad, Claudia Maios, Kai Ruan, Giulio Srubek Tomassy, , Jeffrey Rosenfeld

This paper introduces a new drug-like small molecule series targeting PDI in a multi-protein complex for ALS treatment, showing activity in cellular and animal models.

Journal of Experimental Neurology · Jan 1, 2024Peer-reviewedNeuroscience